相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): a simplified summary
Mohamed A. Hendaus
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2021)
RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19
Yi Jiang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)
Coronavirus Disease 2019 Patients in Earlier Stages Exhaled Millions of Severe Acute Respiratory Syndrome Coronavirus 2 Per Hour
Jianxin Ma et al.
CLINICAL INFECTIOUS DISEASES (2021)
COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays
Xueqing Wang et al.
MEDICINAL RESEARCH REVIEWS (2021)
A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process
Rachel Harwood et al.
LANCET CHILD & ADOLESCENT HEALTH (2021)
被撤回的出版物: Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study (Retracted article. See vol. 167, pg. 277, 2022)
Hany M. Dabbous et al.
ARCHIVES OF VIROLOGY (2021)
6-month consequences of COVID-19 in patients discharged from hospital: a cohort study (Publication with Expression of Concern. See vol. 401, pg. 90, 2023)
Chaolin Huang et al.
LANCET (2021)
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
A. C. Kalil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Mechanism of SARS-CoV-2 polymerase stalling by remdesivir
Goran Kokic et al.
NATURE COMMUNICATIONS (2021)
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
Viviane C. Veiga et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial
Xavier Mariette et al.
LANCET RESPIRATORY MEDICINE (2021)
Emerging treatment strategies for COVID-19 infection
Maria Gavriatopoulou et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2021)
Antivirals for COVID-19: A critical review
Andri Frediansyah et al.
CLINICAL EPIDEMIOLOGY AND GLOBAL HEALTH (2021)
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Manli Wang et al.
CELL RESEARCH (2020)
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
Qiurong Ruan et al.
INTENSIVE CARE MEDICINE (2020)
The outbreak of COVID-19: An overview
Yi-Chi Wu et al.
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2020)
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
Nanshan Chen et al.
LANCET (2020)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang et al.
LANCET (2020)
First Case of 2019 Novel Coronavirus in the United States
Michelle L. Holshue et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
Kimiyasu Shiraki et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
Emmie de Wit et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
Timothy P. Sheahan et al.
NATURE COMMUNICATIONS (2020)
Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
Michael Letko et al.
NATURE MICROBIOLOGY (2020)
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Xueting Yao et al.
CLINICAL INFECTIOUS DISEASES (2020)
COVID-19 in the pediatric population
Ayman Abdelmaksoud et al.
DERMATOLOGIC THERAPY (2020)
Mechanism of baricitinib supports artificial intelligence-predicted testing inCOVID-19 patients
Justin Stebbing et al.
EMBO MOLECULAR MEDICINE (2020)
Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China
Mingkai Tan et al.
IMMUNOLOGY (2020)
A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic
Satyajit Tripathy et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19
D. Praveen et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection
Jacques Fantini et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
Chi Zhang et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Philippe Gautret et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Use of anakinra in severe COVID-19: A case report
Giovanni Filocamo et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Zinc and respiratory tract infections: Perspectives for COVID-19 (Review)
Anatoly Skalny et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2020)
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) A Review
James M. Sanders et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
Calvin J. Gordon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Clinical and immunological features of severe and moderate coronavirus disease 2019
Guang Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Effective treatment of severe COVID-19 patients with tocilizumab
Xiaoling Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
Fabrizio Cantini et al.
JOURNAL OF INFECTION (2020)
Laboratory findings of COVID-19: a systematic review and meta-analysis
Zu-Li Zhang et al.
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION (2020)
COVID-19 epidemic: Disease characteristics in children
Jiatong She et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19
Yong Gao et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
Jianjun Gao et al.
BIOSCIENCE TRENDS (2020)
Use of antiviral drugs to reduce COVID-19 transmission
Oriol Mitja et al.
LANCET GLOBAL HEALTH (2020)
The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin
Ehud Chorin et al.
NATURE MEDICINE (2020)
Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)
Katelyn A. Pastick et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Jason D. Goldman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Remdesivir for the Treatment of Covid-19-Final Report
John H. Beigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19
B. Cao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Mild or Moderate Covid-19
Rajesh T. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19
Yuan Huang et al.
ACTA PHARMACOLOGICA SINICA (2020)
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
Ka-Tim Choy et al.
ANTIVIRAL RESEARCH (2020)
Pathogenesis of COVID-19-induced ARDS: implications for an ageing population
Manuel A. Torres Acosta et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal
Mohammad Sultan Khuroo
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Epidemic update of COVID-19 in Hubei Province compared with other regions in China
Wenjun Du et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Immunomodulatory Drugs in the Management of SARS-CoV-2
Daniel R. Burrage et al.
FRONTIERS IN IMMUNOLOGY (2020)
COVID-19: Specific and Non-Specific Clinical Manifestations and Symptoms: The Current State of Knowledge
Jacek Baj et al.
JOURNAL OF CLINICAL MEDICINE (2020)
RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery
Wei Zhu et al.
SLAS DISCOVERY (2020)
Modeling the Onset of Symptoms of COVID-19
Joseph R. Larsen et al.
FRONTIERS IN PUBLIC HEALTH (2020)
Dexamethasone nanomedicines for COVID-19
Twan Lammers et al.
NATURE NANOTECHNOLOGY (2020)
Cytokine storm induced by SARS-CoV-2
Peipei Song et al.
CLINICA CHIMICA ACTA (2020)
Dexamethasone: A boon for critically ill COVID-19 patients?
Shailesh Kumar Patel et al.
TRAVEL MEDICINE AND INFECTIOUS DISEASE (2020)
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 The CoDEX Randomized Clinical Trial
Bruno M. Tomazini et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Interleukin-6 as prognosticator in patients with COVID-19
Elisa Grifoni et al.
JOURNAL OF INFECTION (2020)
Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Peter W. Horby et al.
LANCET (2020)
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
John H. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Antiviral Drug Discovery To Address the COVID-19 Pandemic
Douglas D. Richman
MBIO (2020)
A living WHO guideline on drugs for covid-19
Francois Lamontagne et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection - United Kingdom and United States, March-August 2020
Sapna Bamrah Morris et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2020)
Targeting the coronavirus SARS-CoV-2: computational insights into the mechanism of action of the protease inhibitors lopinavir, ritonavir and nelfinavir
Giovanni Bolcato et al.
SCIENTIFIC REPORTS (2020)
Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study
Emma J. Kooistra et al.
CRITICAL CARE (2020)
Immunomodulatory-based therapy as a potential promising treatment strategy against severe COVID-19 patients: A systematic review
Mahdieh Razmi et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Anakinra for severe forms of COVID-19: a cohort study
Thomas Huet et al.
LANCET RHEUMATOLOGY (2020)
Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up
Nicola De Rossi et al.
ECLINICALMEDICINE (2020)
Clinical trials on drug repositioning for COVID-19 treatment
Sandro G. Viveiros Rosa et al.
REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH (2020)
Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir
Egor P. Tchesnokov et al.
VIRUSES-BASEL (2019)
Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase
Ariane J. Brown et al.
ANTIVIRAL RESEARCH (2019)
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
Maria L. Agostini et al.
MBIO (2018)
Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy
Amber J. Giles et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Anakinra Therapy for Non-cancer Inflammatory Diseases
Giulio Cavalli et al.
FRONTIERS IN PHARMACOLOGY (2018)
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
Yousuke Furuta et al.
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2017)
Nidovirus RNA polymerases: Complex enzymes handling exceptional RNA genomes
Clara C. Posthuma et al.
VIRUS RESEARCH (2017)
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial
Bita Shakoory et al.
CRITICAL CARE MEDICINE (2016)
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision)
Michael F. Marmor et al.
OPHTHALMOLOGY (2016)
Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset
Jasper Fuk-Woo Chan et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture
Adriaan H. de Wilde et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Therapeutic Role of Anakinra, an Interleukin-1 Receptor Antagonist, in the Management of Secondary Hemophagocytic Lymphohistiocytosis/Sepsis/Multiple Organ Dysfunction/Macrophage Activating Syndrome in Critically III Children
Surender Rajasekaran et al.
PEDIATRIC CRITICAL CARE MEDICINE (2014)
Discovering Thiamine Transporters as Targets of Chloroquine Using a Novel Functional Genomics Strategy
Zhiwei Huang et al.
PLOS GENETICS (2012)
Janus kinases in immune cell signaling
Kamran Ghoreschi et al.
IMMUNOLOGICAL REVIEWS (2009)
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Martin J. Vincent et al.
VIROLOGY JOURNAL (2005)
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
CM Chu et al.
THORAX (2004)
Small molecules targeting severe acute respiratory syndrome human coronavirus
CY Wu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
分享论文
